Skip to main content

Cardiovascular Deal Benchmarks 2026

Median Upfront
$480M
Range: $264M - $757M
Total Deal Value
$2.4B
Range: $1.5B - $3.2B
Royalty Rate
8.7% - 17.4%
Tiered up to 21.4%
Dev Milestones
$416M
Range: $281M - $538M
Model Your Deal

Market Analysis

Cardiovascular licensing deals in 2026 are experiencing renewed activity driven by novel mechanisms in heart failure, PCSK9 follow-ons, and RNA-based therapies for lipid disorders. Phase 2 small molecule deals in the CV space carry a median total deal value of $2.4B, with upfront payments ranging from $264M to $757M. Heart failure with reduced ejection fraction (HFrEF) remains the most actively transacted indication.

CV deal structures emphasize outcomes-driven milestones. Development milestones average $416M, often tied to MACE endpoints and regulatory advisory committee milestones. Regulatory milestones add $530M, while commercial milestones of $946M reflect the large addressable patient populations in cardiovascular disease.

Royalty rates for cardiovascular deals range from 8.7% to 17.4% at the base tier. The CV space is characterized by longer development timelines and larger outcome trials, which compress upfront-to-milestone ratios relative to oncology. However, the blockbuster potential of successfully differentiated CV assets supports escalation tiers reaching 21.4%.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How active is the cardiovascular deal market in 2026?
The CV deal market has rebounded significantly, driven by novel targets such as cardiac myosin inhibitors, soluble guanylate cyclase stimulators, and RNA silencing therapies. Phase 2 CV deals average $2.4B total deal value. The success of recent approvals in HFpEF and hypertrophic cardiomyopathy has reignited licensee interest.
What deal structures are common for PCSK9 and lipid-lowering therapies?
PCSK9 and lipid-lowering deals are structured with moderate upfronts ($480M median) and substantial commercial milestones given the large patient populations. Next-generation PCSK9 approaches (oral small molecules, siRNA) command premiums over follow-on monoclonal antibodies. Annual dosing profiles and improved adherence data are key valuation accelerators.
What drives premium valuations in heart failure licensing deals?
Heart failure deal premiums are driven by demonstrated mortality or hospitalization reduction, novel mechanism of action, favorable safety profiles versus standard of care, and the ability to treat both HFrEF and HFpEF populations. Combination potential with SGLT2 inhibitors and entresto is increasingly valued in deal negotiations.

Related Benchmarks

Metabolic & Obesity Deal Overview

View

Small Molecule Deals

View

Phase 2 Deal Benchmarks

View

Phase 3 Deal Benchmarks

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating